secwatch.observer — SEC 8-K summary
======================================

Issuer:     WEST PHARMACEUTICAL SERVICES INC (WST)
CIK:        0000105770
Form:       8-K
Filed at:   2024-04-25T23:59:59+00:00
Accession:  0000105770-24-000025
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

West Pharma Q1 sales $695.4M (-3%) adj EPS $1.56 (-21%), raises full-year adj EPS guidance
--------------------------------------------------------------------------------

- Reported-diluted EPS $1.55, down 16.2% YoY; adjusted-diluted EPS $1.56, down 21.2%.
- Net sales $695.4M, down 3.0% organically; Proprietary Products sales down 4.0%.
- Full-year 2024 net sales guidance reaffirmed at $3.000-3.025B; adjusted EPS guidance raised to $7.63-7.88 from $7.50-7.75.
- Board declares Q3 dividend $0.20/share, payable Aug 7, 2024 to holders of record Jul 31.
- Repurchased 729,679 shares for $267M at avg $365.87 in Q1.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/105770/000010577024000025/0000105770-24-000025-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/105770/000010577024000025/wst-20240425.htm
  HTML page:      https://secwatch.observer/filing/0000105770-24-000025

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer